Lo N N, Ng R, Song I C, Tan S K
Department of Orthopaedic Surgery O, Singapore General Hospital.
Ann Acad Med Singap. 1995 May;24(3):343-6.
The lack of effectiveness of growth hormone in stimulating the healing of fresh fractures has been attributed to the presence of insufficient precursor osteogenic cells at the fracture site for the growth hormone to exert its influence. We tested the effect of growth hormone on healing in a rabbit non-union model after injection of autogenous marrow cells into the fracture gap. Two millilitres of bone marrow were injected percutaneously into 1 cm diaphyseal defects of rabbit radii. The test group was given subcutaneous human recombinant growth hormone at 0.3 IU/kg/day in divided doses for 2 weeks, while the control group received subcutaneous saline injections. Biomechanical, radiological and callus calcium content assessments were carried out at 4 and 7 weeks. There was significantly increased tensile strength and callus calcium concentration in the group given growth hormone both at 4 and 7 weeks but there was no significant difference in stiffness or in callus volume in the 2 groups. These data suggest that growth hormone can enhance the osteogenic potential of bone marrow as a graft in the treatment of fracture non-union.
生长激素在刺激新鲜骨折愈合方面缺乏有效性,这归因于骨折部位存在不足的前体成骨细胞,以至于生长激素无法发挥其影响。我们在向骨折间隙注射自体骨髓细胞后的兔骨不连模型中测试了生长激素对愈合的影响。将两毫升骨髓经皮注射到兔桡骨1厘米骨干缺损处。试验组以0.3 IU/kg/天的剂量皮下注射重组人生长激素,分剂量给药2周,而对照组接受皮下注射生理盐水。在4周和7周时进行生物力学、放射学和骨痂钙含量评估。在4周和7周时,给予生长激素的组的抗张强度和骨痂钙浓度均显著增加,但两组在刚度或骨痂体积方面无显著差异。这些数据表明,生长激素可以增强骨髓作为移植物在治疗骨折不连中的成骨潜力。